Return to List

Study Summary
No. DM96-060:.......Lymphoma......Anas Younes......Lymphoma/Myeloma
.
Study Summary Title
Study Summary
Number:		DM96-060
Study Title:A Phase II Study of a-Interferon with ABVD for Patients with Hodgkin's Disease
.
Physician New Patient Referral
Name:Anas YounesPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Lymphoma/MyelomaReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-2860
Contact us about clinical trials
.
General Information
Disease Group:LymphomaSupported By:Schering
Phase of Study:Phase IIReturn
Visit:		Every 2 weeks
Treatment
Agents:		Adriamycin
Bleomycin
Dacarbazine
Interferon-2A
Vincristine		Home Care:None
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		N/A
Description/
Intervention:		Unavailable
.
Study Objectives / Outcomes
  • To determine if Interferon a can upregulate Fas ligand and CD30 ligand on T lymphocytes obtained from peripheral blood and lymph nodes of patients with Hodgkin's disease in vivo.
  • To determine the toxicity of Interferon with standard dose ABVD combination.
  • To determine the response rate of Interferon plus ABVD in patients with Hodgkin's disease in phase II study.
    • .
    Study Status Information
    Study Activation / Registration Date:07/25/1996
    IRB Review and Approval Date:11/03/2009
    Study Type:Phase Ii Or Phase I/Ii
    Recruitment Status:Terminated
    Projected Accrual:N/A
    .
    Enrollment Eligibility
    If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
    Inclusion Criteria:1) Hodgkin's disease patients who relapse after radiation therapy alone, or in combination with NOVP; and previously untreated patients with stage III and IV who are eligible for standard ABVD therapy.

    2) Must have adequate bone marrow reserve (ANC > 1,000/uL, Plt > 100,000

    3) LVEF >/= 50%, serum creatinine < 2mg/dl, serum bilirubin < 2mg/dl
    Exclusion Criteria:1) No prior therapy with MOPP.

    2) No servere pulmonary disease including COPD and asthma.
    .
    Links
    Registration Number: NCT01404936
    Study Information on Clinical Trials Registry (clinicaltrials.gov)
    Other Links:
    .
    Results

    Return to Clinical Trials at M.D. Anderson Cancer Center